Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.

ABSTRACT: Subcutaneous semaglutide, at a 2.4 mg once-weekly maintenance dose, is approved in the United States for weight management in individuals with a body mass index (BMI) of 30 kg/m² or higher, or with a BMI of 27 kg/m² or higher and at least one obesity-related co-morbidity. To investigate the usability of the semaglutide pen-injector in individuals who met these criteria, we report post hoc analysis of the summative (human factors validation) usability testing and safety analysis involving patients with type 2 diabetes (an obesity-related co-morbidity) with the same pen-injector, limited to the 26 out of 30 patients with a BMI of 27 kg/m² or higher (11 pen-injector-naïve, 15 pen-injector-experienced) and 15 non-pharmacist healthcare professionals (HCPs). Part

SUBMITTER: Klonoff DC 

PROVIDER: S-EPMC9292194 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature